Cargando…
27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept
Small-gauge vitrectomy has become popular due to its notable advantages, including less trauma, shortened convalescence and improved manoeuvrability. The aim of the present study was to compare the surgical outcomes of 27-gauge (27-G) vitrectomy with those of 25-gauge (25-G) vitrectomy in the manage...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469386/ https://www.ncbi.nlm.nih.gov/pubmed/37664677 http://dx.doi.org/10.3892/etm.2023.12171 |
_version_ | 1785099428335452160 |
---|---|
author | Xiang, Wu Fang, Dong Jiang, Xintong Zhang, Zhaotian Xiang, Chuqi Huang, Shaofen Zhang, Shaochong Wei, Yantao |
author_facet | Xiang, Wu Fang, Dong Jiang, Xintong Zhang, Zhaotian Xiang, Chuqi Huang, Shaofen Zhang, Shaochong Wei, Yantao |
author_sort | Xiang, Wu |
collection | PubMed |
description | Small-gauge vitrectomy has become popular due to its notable advantages, including less trauma, shortened convalescence and improved manoeuvrability. The aim of the present study was to compare the surgical outcomes of 27-gauge (27-G) vitrectomy with those of 25-gauge (25-G) vitrectomy in the management of proliferative diabetic retinopathy (PDR) with preoperative intravitreal injection of conbercept. The data of 48 consecutive patients with PDR (48 eyes) were retrospectively collected. The patients underwent conbercept intravitreal injection and pars plana vitrectomy with a 27-G group (23 eyes) or 25-G group (25 eyes) vitrectomy system. The operating time, suturing rate, endodiathermy rate, postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP) and complications were recorded. The mean postoperative BCVA at final follow-up was significantly improved compared with that at the baseline in both groups (P<0.001 for both). The differences in the mean BCVA changes between the two groups were not significant (P>0.99), and no differences were observed in the final central foveal thickness (P=0.51) between the two groups. The final IOP remained stable compared with that at the baseline in the 27-G group (P=0.36) and the 25-G group (P=0.05). The suturing rate was significantly decreased in the 27-G group compared with the 25-G group (P=0.04). There were no significant differences between the two groups in terms of the operating time (P=0.18), rate of endodiathermy use (P>0.99), iatrogenic retinal breaks (P=0.42) or postoperative recurrent vitreous haemorrhage (P>0.99). In addition, no case of ocular hypotony was observed in either group. In conclusion, 27-G vitrectomy was as efficient and safe as 25-G vitrectomy in the management of PDR in terms of operating time and complications. With reference to the literature, preoperative conbercept injection appears to assist in decreasing the incidence of intraoperative and postoperative complications. |
format | Online Article Text |
id | pubmed-10469386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-104693862023-09-01 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept Xiang, Wu Fang, Dong Jiang, Xintong Zhang, Zhaotian Xiang, Chuqi Huang, Shaofen Zhang, Shaochong Wei, Yantao Exp Ther Med Articles Small-gauge vitrectomy has become popular due to its notable advantages, including less trauma, shortened convalescence and improved manoeuvrability. The aim of the present study was to compare the surgical outcomes of 27-gauge (27-G) vitrectomy with those of 25-gauge (25-G) vitrectomy in the management of proliferative diabetic retinopathy (PDR) with preoperative intravitreal injection of conbercept. The data of 48 consecutive patients with PDR (48 eyes) were retrospectively collected. The patients underwent conbercept intravitreal injection and pars plana vitrectomy with a 27-G group (23 eyes) or 25-G group (25 eyes) vitrectomy system. The operating time, suturing rate, endodiathermy rate, postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP) and complications were recorded. The mean postoperative BCVA at final follow-up was significantly improved compared with that at the baseline in both groups (P<0.001 for both). The differences in the mean BCVA changes between the two groups were not significant (P>0.99), and no differences were observed in the final central foveal thickness (P=0.51) between the two groups. The final IOP remained stable compared with that at the baseline in the 27-G group (P=0.36) and the 25-G group (P=0.05). The suturing rate was significantly decreased in the 27-G group compared with the 25-G group (P=0.04). There were no significant differences between the two groups in terms of the operating time (P=0.18), rate of endodiathermy use (P>0.99), iatrogenic retinal breaks (P=0.42) or postoperative recurrent vitreous haemorrhage (P>0.99). In addition, no case of ocular hypotony was observed in either group. In conclusion, 27-G vitrectomy was as efficient and safe as 25-G vitrectomy in the management of PDR in terms of operating time and complications. With reference to the literature, preoperative conbercept injection appears to assist in decreasing the incidence of intraoperative and postoperative complications. D.A. Spandidos 2023-08-17 /pmc/articles/PMC10469386/ /pubmed/37664677 http://dx.doi.org/10.3892/etm.2023.12171 Text en Copyright: © Xiang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Xiang, Wu Fang, Dong Jiang, Xintong Zhang, Zhaotian Xiang, Chuqi Huang, Shaofen Zhang, Shaochong Wei, Yantao 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
title | 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
title_full | 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
title_fullStr | 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
title_full_unstemmed | 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
title_short | 27‑Gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
title_sort | 27‑gauge vitrectomy vs. 25‑gauge vitrectomy in the management of proliferative diabetic retinopathy with preoperative intravitreal injection of conbercept |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469386/ https://www.ncbi.nlm.nih.gov/pubmed/37664677 http://dx.doi.org/10.3892/etm.2023.12171 |
work_keys_str_mv | AT xiangwu 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT fangdong 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT jiangxintong 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT zhangzhaotian 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT xiangchuqi 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT huangshaofen 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT zhangshaochong 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept AT weiyantao 27gaugevitrectomyvs25gaugevitrectomyinthemanagementofproliferativediabeticretinopathywithpreoperativeintravitrealinjectionofconbercept |